세계의 자가전증 치료제 시장 보고서(2024년)

Preeclampsia Drugs Global Market Report 2024

US $ 5,000 ￦ 6,977,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 7,500 ￦ 10,465,000

PDF (Site License)

PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 10,000 ￦ 13,954,000

PDF (Enterprise License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

자가전증 치료제 시장 규모는 최근 몇 년동안 빠르게 성장하여 2023년 11억 3,000만 달러에서 2024년에는 12억 5,000만 달러에 달하고, CAGR 10.7%로 성장할 것으로 예상됩니다. 실적 기간의 성장은 임산부 건강 인식 향상, 연구 개발, 신생아 건강 문제, 조기 발견에 기인합니다.

임신성 고혈압 치료제 시장 규모는 향후 몇 년동안 빠르게 성장할 것으로 예상되며, 2028년에는 연평균 10.9%의 연평균 복합 성장률(CAGR)로 18억 9,000만 달러에 달할 것으로 예상됩니다. 예측 기간의 성장은 개인 맞춤형 의료, 비침습적 진단 도구, 표적 치료, 건강 형평성에 대한 노력에 기인합니다. 예측 기간의 주요 동향으로는 예방 전략, 환자 중심 치료, 지속적인 모니터링, 규제 강화 등이 있습니다.

임산부의 당뇨병 발병률 증가는 향후 임신성 고혈압 치료제 시장의 성장을 견인할 것으로 예상됩니다. 당뇨병은 혈당 상승을 특징으로 하는 만성 대사성 질환으로 자간전증 등 임신에 악영향을 미칠 수 있는 질환입니다. 메트포르민은 자간전증 치료에 사용되는 약물로 자간전증 발병 위험이 있는 임산부에게 널리 사용되며, 2022년 12월 현재 미국 생물 의학 도서관 및 정보 센터인 국립 의학 도서관의 데이터에 따르면 2022년 임신성 당뇨병(GDM) 사례는 총 20,865건으로 6.56% 증가율을 보이고 있습니다. 이에 따라 임산부 당뇨병 환자의 급증은 자가전증 치료제 시장 성장의 원동력이 될 것으로 예상됩니다.

생활습관병 증가는 임신성 고혈압 치료제 시장의 성장을 가속할 것입니다. 생활습관병은 비감염성 질환(NCD)이라고도 불리며, 주로 건강에 해로운 생활습관 선택과 행동으로 인한 건강 상태의 그룹을 포괄합니다. 임신성 고혈압신증 치료제는 자간전증의 위험요인인 고혈압, 비만, 당뇨병과 같은 생활습관병 치료에 도움이 되고 있습니다. 예를 들어, 스위스에 본부를 둔 유엔 전문기구인 세계보건기구(WHO)가 2022년 9월에 보고한 바에 따르면, 전 세계 연간 사망자 4100만 명 중 비감염성 질환(NCDs) 또는 만성질환이 74%를 차지합니다. 심혈관 질환으로 인한 사망자 1,790만 명, 암으로 인한 사망자 930만 명, 만성 호흡기 질환으로 인한 사망자 410만 명, 당뇨병으로 인한 사망자 200만 명입니다. 이에 따라 생활습관병의 급증은 임신성 고혈압 치료제 시장의 성장을 가속하는 요인으로 작용하고 있습니다.

2023년 자가전증 치료제 시장에서 가장 규모가 큰 지역은 북미였습니다. 자가전증 치료제 보고서의 대상 지역은 아시아태평양, 서유럽, 중동 및 북유럽, 북미, 남미, 중동 및 아프리카입니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 거시경제 시나리오

• 고인플레이션이 시장에 미치는 영향
• 우크라이나·러시아 전쟁이 시장에 미치는 영향
• 시장에 대한 COVID-19의 영향

제5장 세계 시장 규모와 성장

• 세계 시장 성장 촉진요인과 억제요인
  • 시장 성장 촉진요인
  • 시장 성장 억제요인
• 세계 시장 규모 실적과 성장, 2018년-2023년
• 세계 시장 규모 예측과 성장, 2023년-2028년, 2033년

제6장 시장 세분화

• 세계의 임신 고혈압 신증 치료제 시장, 유형별 세분화, 분석 및 예측, 2018-2023년,2023-2028년, 2033년
• 경도
• 중증
• 세계의 임신 고혈압 신증 치료제 시장, 치료별 세분화, 분석 및 예측, 2018-2023년,2023-2028년, 2033년
• 고혈압(BP) 약물 요법
• 코르티코스테로이드
• 항경련제
• 세계의 임신 고혈압 신증 치료제 시장, 투여 경로별 세분화, 분석 및 예측, 2018-2023년,2023-2028년, 2033년
• 경구
• 비경구
• 기타 투여 경로
• 세계의 임신 고혈압 신증 치료제 시장, 유통 채널별 세분화, 분석 및 예측, 2018-2023년,2023-2028년, 2033년
• 병원 약국
• 소매 약국
• 온라인 약국
• 기타 유통 채널
• 세계의 자간전증 약시장, 최종사용자별 세분화, 분석 및 예측, 2018-2023,2023-2028년, 2033년
• 병원
• 전문 클리닉
• 진단센터
• 기타 최종사용자

제7장 지역 및 국가별 분석

• 세계의 임신 고혈압 신증 치료제 시장, 지역별, 분석 및 예측, 2018-2023,2023-2028년, 2033년
• 세계의 임신 고혈압 신증 치료제 시장, 국가별, 분석 및 예측, 2018-2023,2023-2028년, 2033년

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 개요

• 자간전증 약시장 경쟁 구도
• 자간전증 약시장 기업 개요
  • AbbVie Inc.
  • Pfizer Inc.
  • Johnson &Johnson Co
  • F. Hoffmann-La Roche Ltd.
  • Merck &Co. Inc.

제31장 기타 주요 및 혁신적인 기업

• Novartis AG
• Sanofi S.A.
• Celgene Corp
• Thermo Fisher Scientific Inc.
• AstraZeneca plc
• Abbott Laboratories
• GlaxoSmithKline PLC
• Takeda Pharmaceuticals Company Limited
• Eli Lilly and Company
• Gilead Sciences Inc.
• Amgen Inc.
• Siemens Healthcare GmbH
• Boehringer Ingelheim Group
• Viatris Inc.
• Baxter International Inc.

제32장 경쟁 벤치마킹

제33장 경쟁 대시보드

제34장 주요 인수합병(M&A)

제35장 향후 전망과 가능성 분석

제36장 부록

LSH

영문 목차

영문목차

“Preeclampsia Drugs Global Market Report 2024 ” from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on preeclampsia drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
• Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
• Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
• Measure the impact of high global inflation on market growth.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for preeclampsia drugs? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? “The preeclampsia drugs market global report ” from The Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

Scope

Markets Covered:

• 1) By Type: Mild Preeclampsia; Severe Preeclampsia
• 2) By Treatment: Medication to Lower Hypertension (B.P); Corticosteroids; Anticonvulsants Medication
• 3) By Route of Administration: Oral; Parenteral; Other Route of Administration
• 4) By Distribution Channel: Hospital Pharmacy; Retail Pharmacy; Online Pharmacies; Other Distribution Channels
• 5) By End-User: Hospitals; Specialty Clinics; Diagnostic Centers; Other End-Users
• Companies Mentioned: AbbVie Inc.; Pfizer Inc.; Johnson & Johnson Co; F. Hoffmann-La Roche Ltd.; Merck & Co. Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Executive Summary

Preeclampsia drugs are medications used to manage and treat preeclampsia, a serious pregnancy complication characterized by high blood pressure and organ damage, particularly in the liver and kidneys. Healthcare professionals typically prescribe these drugs to pregnant women diagnosed with preeclampsia to help reduce blood pressure and prevent further complications.

The main types of preeclampsia drugs are categorized into treatments for mild preeclampsia and severe preeclampsia. Mild preeclampsia is a medical disorder that can affect pregnant women, often appearing after the 20th week of pregnancy. Treatment options for preeclampsia include medications to lower blood pressure, corticosteroids, and anticonvulsant medication. These drugs can be administered through various routes, including the oral route and parenteral (injectable) route. They are available through different distribution channels such as hospital pharmacies, retail pharmacies, online pharmacies, and others. Preeclampsia drugs are utilized by various end-users, including hospitals, specialty clinics, diagnostic centers, and other relevant healthcare facilities.

The preeclampsia drug market research report is one of a series of new reports from The Business Research Company that provides preeclampsia drug market statistics, including preeclampsia drug industry global market size, regional shares, competitors with a preeclampsia drug market share, detailed preeclampsia drug market segments, market trends and opportunities and any further data you may need to thrive in the preeclampsia drug industry. This preeclampsia drug market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The preeclampsia drugs market size has grown rapidly in recent years. It will grow from $1.13 billion in 2023 to $1.25 billion in 2024 at a compound annual growth rate (CAGR) of 10.7%. The growth in the historic period can be attributed to increased maternal health awareness, research and development, neonatal health concerns, early detection.

The preeclampsia drugs market size is expected to see rapid growth in the next few years. It will grow to $1.89 billion in 2028 at a compound annual growth rate (CAGR) of 10.9%. The growth in the forecast period can be attributed to personalized medicine, non-invasive diagnostic tools, targeted therapies, health equity initiatives. Major trends in the forecast period include preventive strategies, patient-centered care, continuous monitoring, regulatory focus.

The increasing incidence of diabetes among pregnant women is anticipated to drive the expansion of the preeclampsia drug market in the future. Diabetes is a chronic metabolic disease characterized by elevated levels of blood glucose, and it can lead to detrimental effects on pregnancy, including preeclampsia. Metformin, a medication used in the management of preeclampsia, finds significant application among pregnant women at risk of developing this condition. As of December 2022, data from the National Library of Medicine, a US-based biomedical library and informatics center, reported a total of 20,865 cases of gestational diabetes mellitus (GDM) in 2022, signifying a 6.56% increase. Consequently, the upsurge in diabetes cases among pregnant women is expected to be a driving force behind the preeclampsia drug market's growth.

The increasing prevalence of lifestyle diseases is poised to stimulate the expansion of the preeclampsia drugs market. Lifestyle diseases, also known as non-communicable diseases (NCDs), encompass a group of health conditions primarily attributed to unhealthy lifestyle choices and behaviors. Preeclampsia drugs are instrumental in treating lifestyle-related ailments such as hypertension, obesity, and diabetes, all of which represent risk factors for preeclampsia. For example, in September 2022, as reported by the World Health Organization, a specialized agency of the United Nations based in Switzerland, non-communicable diseases (NCDs) or chronic diseases accounted for 74% of the 41 million global annual deaths. This included 17.9 million deaths due to cardiovascular diseases, 9.3 million deaths from cancer, 4.1 million deaths related to chronic respiratory diseases, and 2.0 million deaths associated with diabetes. Consequently, the burgeoning prevalence of lifestyle diseases is a key driver behind the growth of the preeclampsia drugs market.

Insufficient investments act as a constraint and may impede the growth of the preeclampsia drugs market during the forecast period. The lack of financial support for preeclampsia drug development creates a substantial barrier for patients. It results in a restricted pipeline of new drug candidates, increased research costs, limited public funding, reduced access to treatments, heightened healthcare expenses, and a diminished quality of life for affected individuals. For example, in 2022, as reported by the National Library of Medicine, a biomedical library, insufficient funding has resulted in a scarcity of preeclampsia medications in the market. Less than 1% of the 153 candidates have reached the market for this indication, with less than 9% being recommended in international guidelines or incorporated into routine clinical practice. Consequently, the lack of investments presents a hindrance to the growth of the preeclampsia drug market.

Prominent companies operating in the preeclampsia medicine market are actively engaged in the development of advanced drug solutions to bolster their market presence. For instance, in March 2023, Comanche Biopharma Corp., a US-based biopharmaceutical company, announced the FDA's approval of an investigational new drug (IND) application for CBP-4888, Comanche's unique siRNA therapy designed for preeclampsia treatment. CBP-4888 is a subcutaneously administered siRNA therapy that reduces the production of soluble fms-like tyrosine kinase-1 (sFLT1) in the placenta. Excessive production of the sFLT1 protein in the placenta is the primary cause of preeclampsia, as it enters the mother's circulation. CBP-4888 has the potential to alleviate preeclampsia symptoms, including high blood pressure and organ damage, and may enable the safe extension of pregnancy.

In October 2022, Ginkgo Bioworks Inc., a US-based provider of advanced biological technology, acquired Zymergen Inc. for an undisclosed amount. This acquisition strengthens Ginkgo's platform by integrating essential automation and software capabilities while bringing a wealth of experience in diverse biological engineering. Zymergen Inc., a US-based biotechnology company specializing in preeclampsia treatments, complements Ginkgo's biotechnology portfolio.

Major players in the preeclampsia drugs market are AbbVie Inc., Pfizer Inc., Johnson & Johnson Co, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Novartis AG, Sanofi S.A., Celgene Corp, Thermo Fisher Scientific Inc., AstraZeneca PLC, Abbott Laboratories, GlaxoSmithKline PLC, Takeda Pharmaceuticals Company Limited, Eli Lilly and Company, Gilead Sciences Inc., Amgen Inc., Siemens Healthcare GmbH, Boehringer Ingelheim Group, Viatris Inc., Baxter International Inc., Teva Pharmaceutical Industries Ltd., Union Chimique Belge SA, Otsuka Pharmaceutical Co. Ltd., Kyowa Kirin Co Ltd., Mallinckrodt Pharmaceuticals Limited, Comanche Biopharma Corp, Genentech Inc., Diabetomics Inc.

North America was the largest region in the preeclampsia drugs market in 2023. The regions covered in preeclampsia drugs report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the preeclampsia drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, and Spain.

The preeclampsia drugs market consists of sales of labetalol, methyldopa and magnesium sulfate (prevent seizures). Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Table of Contents

1. Executive Summary

2. Preeclampsia Drugs Market Characteristics

3. Preeclampsia Drugs Market Trends And Strategies

4. Preeclampsia Drugs Market - Macro Economic Scenario

• 4.1. Impact Of High Inflation On The Market
• 4.2. Ukraine-Russia War Impact On The Market
• 4.3. COVID-19 Impact On The Market

5. Global Preeclampsia Drugs Market Size and Growth

• 5.1. Global Preeclampsia Drugs Market Drivers and Restraints
  • 5.1.1. Drivers Of The Market
  • 5.1.2. Restraints Of The Market
• 5.2. Global Preeclampsia Drugs Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
• 5.3. Global Preeclampsia Drugs Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Preeclampsia Drugs Market Segmentation

• 6.1. Global Preeclampsia Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Mild Preeclampsia
• Severe Preeclampsia
• 6.2. Global Preeclampsia Drugs Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Medication to Lower Hypertension (B.P)
• Corticosteroids
• Anticonvulsants Medication
• 6.3. Global Preeclampsia Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Oral
• Parenteral
• Other Route of Administrations
• 6.4. Global Preeclampsia Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacies
• Other Distribution Channels
• 6.5. Global Preeclampsia Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Hospitals
• Specialty Clinics
• Diagnostic Centres
• Other End-Users

7. Preeclampsia Drugs Market Regional And Country Analysis

• 7.1. Global Preeclampsia Drugs Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 7.2. Global Preeclampsia Drugs Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Preeclampsia Drugs Market

• 8.1. Asia-Pacific Preeclampsia Drugs Market Overview
• Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Preeclampsia Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 8.3. Asia-Pacific Preeclampsia Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 8.4. Asia-Pacific Preeclampsia Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Preeclampsia Drugs Market

• 9.1. China Preeclampsia Drugs Market Overview
• 9.2. China Preeclampsia Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
• 9.3. China Preeclampsia Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
• 9.4. China Preeclampsia Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Preeclampsia Drugs Market

• 10.1. India Preeclampsia Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 10.2. India Preeclampsia Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 10.3. India Preeclampsia Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Preeclampsia Drugs Market

• 11.1. Japan Preeclampsia Drugs Market Overview
• 11.2. Japan Preeclampsia Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 11.3. Japan Preeclampsia Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 11.4. Japan Preeclampsia Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Preeclampsia Drugs Market

• 12.1. Australia Preeclampsia Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 12.2. Australia Preeclampsia Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 12.3. Australia Preeclampsia Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Preeclampsia Drugs Market

• 13.1. Indonesia Preeclampsia Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 13.2. Indonesia Preeclampsia Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 13.3. Indonesia Preeclampsia Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Preeclampsia Drugs Market

• 14.1. South Korea Preeclampsia Drugs Market Overview
• 14.2. South Korea Preeclampsia Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 14.3. South Korea Preeclampsia Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 14.4. South Korea Preeclampsia Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Preeclampsia Drugs Market

• 15.1. Western Europe Preeclampsia Drugs Market Overview
• 15.2. Western Europe Preeclampsia Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 15.3. Western Europe Preeclampsia Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 15.4. Western Europe Preeclampsia Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Preeclampsia Drugs Market

• 16.1. UK Preeclampsia Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 16.2. UK Preeclampsia Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 16.3. UK Preeclampsia Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Preeclampsia Drugs Market

• 17.1. Germany Preeclampsia Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 17.2. Germany Preeclampsia Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 17.3. Germany Preeclampsia Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Preeclampsia Drugs Market

• 18.1. France Preeclampsia Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 18.2. France Preeclampsia Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 18.3. France Preeclampsia Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Preeclampsia Drugs Market

• 19.1. Italy Preeclampsia Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 19.2. Italy Preeclampsia Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 19.3. Italy Preeclampsia Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Preeclampsia Drugs Market

• 20.1. Spain Preeclampsia Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 20.2. Spain Preeclampsia Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 20.3. Spain Preeclampsia Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Preeclampsia Drugs Market

• 21.1. Eastern Europe Preeclampsia Drugs Market Overview
• 21.2. Eastern Europe Preeclampsia Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 21.3. Eastern Europe Preeclampsia Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 21.4. Eastern Europe Preeclampsia Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Preeclampsia Drugs Market

• 22.1. Russia Preeclampsia Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 22.2. Russia Preeclampsia Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 22.3. Russia Preeclampsia Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Preeclampsia Drugs Market

• 23.1. North America Preeclampsia Drugs Market Overview
• 23.2. North America Preeclampsia Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 23.3. North America Preeclampsia Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 23.4. North America Preeclampsia Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Preeclampsia Drugs Market

• 24.1. USA Preeclampsia Drugs Market Overview
• 24.2. USA Preeclampsia Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 24.3. USA Preeclampsia Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 24.4. USA Preeclampsia Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Preeclampsia Drugs Market

• 25.1. Canada Preeclampsia Drugs Market Overview
• 25.2. Canada Preeclampsia Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 25.3. Canada Preeclampsia Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 25.4. Canada Preeclampsia Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Preeclampsia Drugs Market

• 26.1. South America Preeclampsia Drugs Market Overview
• 26.2. South America Preeclampsia Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 26.3. South America Preeclampsia Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 26.4. South America Preeclampsia Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Preeclampsia Drugs Market

• 27.1. Brazil Preeclampsia Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 27.2. Brazil Preeclampsia Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 27.3. Brazil Preeclampsia Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Preeclampsia Drugs Market

• 28.1. Middle East Preeclampsia Drugs Market Overview
• 28.2. Middle East Preeclampsia Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 28.3. Middle East Preeclampsia Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 28.4. Middle East Preeclampsia Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Preeclampsia Drugs Market

• 29.1. Africa Preeclampsia Drugs Market Overview
• 29.2. Africa Preeclampsia Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 29.3. Africa Preeclampsia Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 29.4. Africa Preeclampsia Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Preeclampsia Drugs Market Competitive Landscape And Company Profiles

• 30.1. Preeclampsia Drugs Market Competitive Landscape
• 30.2. Preeclampsia Drugs Market Company Profiles
  • 30.2.1. AbbVie Inc.
    • 30.2.1.1. Overview
    • 30.2.1.2. Products and Services
    • 30.2.1.3. Strategy
    • 30.2.1.4. Financial Performance
  • 30.2.2. Pfizer Inc.
    • 30.2.2.1. Overview
    • 30.2.2.2. Products and Services
    • 30.2.2.3. Strategy
    • 30.2.2.4. Financial Performance
  • 30.2.3. Johnson & Johnson Co
    • 30.2.3.1. Overview
    • 30.2.3.2. Products and Services
    • 30.2.3.3. Strategy
    • 30.2.3.4. Financial Performance
  • 30.2.4. F. Hoffmann-La Roche Ltd.
    • 30.2.4.1. Overview
    • 30.2.4.2. Products and Services
    • 30.2.4.3. Strategy
    • 30.2.4.4. Financial Performance
  • 30.2.5. Merck & Co. Inc.
    • 30.2.5.1. Overview
    • 30.2.5.2. Products and Services
    • 30.2.5.3. Strategy
    • 30.2.5.4. Financial Performance

31. Preeclampsia Drugs Market Other Major And Innovative Companies

• 31.1. Novartis AG
• 31.2. Sanofi S.A.
• 31.3. Celgene Corp
• 31.4. Thermo Fisher Scientific Inc.
• 31.5. AstraZeneca plc
• 31.6. Abbott Laboratories
• 31.7. GlaxoSmithKline PLC
• 31.8. Takeda Pharmaceuticals Company Limited
• 31.9. Eli Lilly and Company
• 31.10. Gilead Sciences Inc.
• 31.11. Amgen Inc.
• 31.12. Siemens Healthcare GmbH
• 31.13. Boehringer Ingelheim Group
• 31.14. Viatris Inc.
• 31.15. Baxter International Inc.

32. Global Preeclampsia Drugs Market Competitive Benchmarking

33. Global Preeclampsia Drugs Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Preeclampsia Drugs Market

35. Preeclampsia Drugs Market Future Outlook and Potential Analysis

• 35.1 Preeclampsia Drugs Market In 2028 - Countries Offering Most New Opportunities
• 35.2 Preeclampsia Drugs Market In 2028 - Segments Offering Most New Opportunities
• 35.3 Preeclampsia Drugs Market In 2028 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer

관련자료